Immune checkpoint blockade has redefined cancer therapy, yet durable responses remain constrained by resistance states that arise from coordinated tumor-cell, immune, stromal, vascular, lymphatic, and metabolic programs rather than from a single defective pathway. This review develops a translational framework in which tumor-intrinsic immune invisibility, myeloid and regulatory lymphocyte suppression, defective dendritic-cell priming, stromal and vascular exclusion, lymphatic control of antigen drainage, metabolic stress, and ILC2/type 2 immune plasticity are interpreted as interdependent ecosystem states. We discuss therapeutic strategies that reprogram these states, including myeloid and Treg modulation, stromal and vascular remodeling, preservation or restoration of productive lymphatic communication, cytokine and metabolic interventions, alternative checkpoint blockade, oncolytic viruses, vaccines, engineered cell therapies, and nanomedicine-enabled local delivery. Emphasis is placed on the lessons of failed or modestly effective trials, which show that biologically plausible interventions often fail when the dominant resistance bottleneck is not defined, tissue target engagement is not verified, or treatment sequence is not matched to the immune architecture of the tumor. We propose that future progress will depend on ecosystem-matched combinations guided by spatial biomarkers, on-treatment pharmacodynamics, and adaptive trial designs capable of linking mechanism to clinical decision-making.
Wang et al. (Fri,) studied this question.